Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.
Privé BM, Janssen MJR, van Oort IM, Muselaers CHJ, Jonker MA, de Groot M, Mehra N, Verzijlbergen JF, Scheenen TWJ, Zámecnik P, Barentsz JO, Gotthardt M, Noordzij W, Vogel WV, Bergman AM, van der Poel HG, Vis AN, Oprea-Lager DE, Gerritsen WR, Witjes JA, Nagarajah J.
Privé BM, et al. Among authors: bergman am.
BMC Cancer. 2020 Sep 14;20(1):884. doi: 10.1186/s12885-020-07386-z.
BMC Cancer. 2020.
PMID: 32928177
Free PMC article.
Clinical Trial.